title: [An 18 month evaluation of MM-MTA pulpotomy on primary decayed molars].
abstract: Pulpotomy is the most performed and controversial therapeutic in pediatric dentistry. Formocresol is known to have a toxic effect on living tissues, a mutagenic and carcinogenic potential with a systemic uptake of formocresol via pulpotomized teeth, other alternative products have been investigated. 40 molars were pulpotomized using Micro Mega Mineral Trioxide Aggregate (MM-MTA), which eliminates the need for the use of formocresol. The effects of this material were evaluated both clinically and radiographically. Post-operative control examinations were performed at 1, 6, 12, and 18 months trying to detect spontaneous or stimulated pain, pathological tooth mobility, abscesses or fistulas, internal or external pathological tooth resorption, periapical bone destruction, or canal obliteration. Pain was absent at 18 months post operatively. Thirty six molar treated with the MM-MTA didn't show any mobility or pain, one molar presented a pathological resorption and one molar presented an abscess without a fistula at 12 month. The observations were compared to others related to formocresol, ferric sulfate, MTA, and laser pulpotomies, using the Chi-square test x2. The abundance of positive result strongly demonstrate that the MM-MTA pulpotomy on carious temporary molars is a promising technique.
authors.forename: J C
authors.initials: JC
authors.lastname: Abou Chedid
authors.forename: N
authors.initials: N
authors.lastname: Mchayleh
authors.forename: I
authors.initials: I
authors.lastname: Khalil
authors.forename: B
authors.initials: B
authors.lastname: Melki
authors.forename: L S
authors.initials: LS
authors.lastname: Hardan
mesh_terms: D000038:Abscess / Q000145:classification; D017607:Aluminum Compounds / Q000627:therapeutic use*; D002119:Calcium Carbonate / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D002648:Child; D003731:Dental Caries / Q000628:therapy*; D003751:Dental Fistula / Q000145:classification; D003786:Dental Pulp Cavity / Q000187:drug effects; D003793:Dental Restoration, Permanent / Q000379:methods; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005899:Glass Ionomer Cements / Q000737:chemistry; D006801:Humans; D008297:Male; D008963:Molar / Q000000981:diagnostic imaging / Q000473:pathology*; D010087:Oxides / Q000627:therapeutic use*; D010483:Periapical Diseases / Q000145:classification; D011446:Prospective Studies; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011672:Pulpotomy / Q000379:methods*; D011859:Radiography; D017640:Silicates / Q000627:therapeutic use*; D014086:Tooth Mobility / Q000145:classification; D014091:Tooth Resorption / Q000145:classification; D014094:Tooth, Deciduous / Q000000981:diagnostic imaging / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D005899:Glass Ionomer Cements; D010087:Oxides; D057872:Pulp Capping and Pulpectomy Agents; D017640:Silicates; C086631:mineral trioxide aggregate; D002119:Calcium Carbonate